Search Results

The SanBio Group today announced it is one of the founding member organizations of the National TBI Registry Coalition (NTRC) in the United States.

The SanBio Group hereby announces the completion of an application filing with Japan’s Ministry of Health, Labour, and Welfare for manufacture and marketing approval as a regenerative medicine product for the investigational product SB623, as a treatment for chronic motor deficit from traumatic brain injury.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

The SanBio Group, hereby announce that data comparing outcome measures for persons with traumatic brain injury living with chronic motor deficits was published in Expert Review of Neurotherapeutics.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients